Empagliflozin Attenuates Renal and Urinary Markers of Tubular Epithelial Cell Injury in Streptozotocin-induced Diabetic Rats

被引：0
作者：
Zahra Ashrafi Jigheh
Amir Ghorbani Haghjo
Hassan Argani
Leila Roshangar
Nadereh Rashtchizadeh
Davoud Sanajou
Saeed Nazari Soltan Ahmad
Jalil Rashedi
Siavoush Dastmalchi
Mehran Mesgari Abbasi
机构：
[1] Tabriz University of Medical Sciences,Department of Biochemistry, Faculty of Medicine
[2] Tabriz University of Medical Sciences,Student Research Center
[3] Tabriz University of Medical Sciences,Biotechnology Research Center
[4] Beheshti University of Medical Sciences,Urology and Nephrology Research Center
[5] Tabriz University of Medical Sciences,Stem Cell Research Center
[6] Tabriz University of Medical Sciences,Drug Applied Research Center
来源：
Indian Journal of Clinical Biochemistry | 2020年 / 35卷
关键词：
Diabetic nephropathy; Empagliflozin; Tubular injury markers;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Empagliflozin, a SGLT-2 inhibitor, improves diabetic nephropathy through its pleiotropic anti-inflammatory effects. The present study aims to evaluate empagliflozin effects on renal and urinary levels of tubular epithelial cell injury markers in streptozotocin-induced diabetic rats. Empagliflozin at 10 mg/kg (p.o.) was administered for 4 weeks, beginning 8 weeks after induction of diabetes. Renal function as well as markers of renal tubular epithelial cell injury were assessed in kidney tissue homogenates and urine. Empagliflozin was able to ameliorate diabetes induced elevations in serum cystatin C levels. It also alleviated renal KIM-1/NGAL levels and urinary albumin, α-GST, and RBP excretions. In addition to decreasing urinary levels of cell cycle arrest indices i.e. TIMP-2 and IGFBP7, empagliflozin mitigated acetylated NF-κB levels in renal tissues of diabetic rats. As a whole, these findings reveal empagliflozin capability in improving diabetic nephropathy via ameliorating indices of renal inflammation, injury, and cell cycle arrest on streptozotocin-induced diabetic rats.
引用
收藏
页码：109 / 114
页数：5
相关论文
共 126 条
  • [1] Nichols GA(2011)Medical care costs associated with progression of diabetic nephropathy Diabetes Care 34 2374-2378
  • [2] Vupputuri S(2013)Mechanisms of diabetic complications Physiol Rev 93 137-188
  • [3] Lau H(2010)Pathologic classification of diabetic nephropathy J Am Soc Nephrol 21 556-563
  • [4] Forbes JM(2012)The pathogenic role of the renal proximal tubular cell in diabetic nephropathy Nephrol Dial Transplant 27 3049-3056
  • [5] Cooper ME(2008)Effect of a multifactorial intervention on mortality in type 2 diabetes N Engl J Med 358 580-591
  • [6] Tervaert TWC(2009)Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes Diabetes Care 32 2068-2074
  • [7] Mooyaart AL(2009)Glucose control and vascular complications in veterans with type 2 diabetes N Engl J Med 360 129-139
  • [8] Amann K(2013)Combined angiotensin inhibition for the treatment of diabetic nephropathy N Engl J Med 369 1892-1903
  • [9] Cohen AH(2017)Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME Eur Heart J 39 363-370
  • [10] Cook HT(2015) trial Curr Opin Nephrol Hypertens 24 96-103
12345678910